TECHNODRUG Stock Overview
Manufactures and sells human and veterinary medicines in Bangladesh and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Techno Drugs Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ৳42.30 |
| 52 Week High | ৳42.30 |
| 52 Week Low | ৳29.00 |
| Beta | 0 |
| 11 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 60.23% |
Recent News & Updates
Recent updates
Shareholder Returns
| TECHNODRUG | BD Pharmaceuticals | BD Market | |
|---|---|---|---|
| 7D | 20.9% | -0.5% | -0.5% |
| 1Y | n/a | -18.2% | -20.4% |
Return vs Industry: Insufficient data to determine how TECHNODRUG performed against the BD Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how TECHNODRUG performed against the BD Market.
Price Volatility
| TECHNODRUG volatility | |
|---|---|
| TECHNODRUG Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 7.0% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in BD Market | 7.4% |
| 10% least volatile stocks in BD Market | 3.6% |
Stable Share Price: TECHNODRUG's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine TECHNODRUG's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 1,518 | Shah Jalal Ahmed | www.technodrugsltd.com |
Techno Drugs Ltd. manufactures and sells human and veterinary medicines in Bangladesh and internationally. It also offers oncology medicines. The company was incorporated in 2009 and is based in Dhaka, Bangladesh.
Techno Drugs Ltd. Fundamentals Summary
| TECHNODRUG fundamental statistics | |
|---|---|
| Market cap | ৳5.51b |
| Earnings (TTM) | ৳195.51m |
| Revenue (TTM) | ৳2.73b |
28.2x
P/E Ratio2.0x
P/S RatioIs TECHNODRUG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TECHNODRUG income statement (TTM) | |
|---|---|
| Revenue | ৳2.73b |
| Cost of Revenue | ৳1.58b |
| Gross Profit | ৳1.15b |
| Other Expenses | ৳958.54m |
| Earnings | ৳195.51m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.50 |
| Gross Margin | 42.22% |
| Net Profit Margin | 7.15% |
| Debt/Equity Ratio | 101.7% |
How did TECHNODRUG perform over the long term?
See historical performance and comparison